Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Stock Has Average Price Target of $22.29

Key Points

• Analysts remain moderately bullish: Arcturus Therapeutics has a consensus “Moderate Buy” rating from 10 analysts, with an average 12-month price target of $22.29 versus a recent share price of $11.03.
• Recent recommendations were mixed but generally positive: Citigroup upgraded the stock to “buy,” Zacks raised it to “strong buy,” and Leerink Partners increased its target to $19, while BTIG lowered its target to $20 but maintained a “buy” rating.
• The company remains financially challenged: Arcturus beat quarterly EPS estimates but reported only $2.96 million in revenue, negative margins and return on equity; institutional investors own 94.54% of the stock.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Get Free Report) has earned a consensus rating of "Moderate Buy" from the ten ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, six have issued a buy rating and two have given a strong buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $22.29.

ARCT has been the subject of a number of recent analyst reports. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research report on Thursday, September 24th. Citigroup upgraded shares of Arcturus Therapeutics from a "neutral" rating to a "buy" rating and boosted their price target for the company from $8.00 to $20.00 in a research report on Thursday, September 24th. Zacks Research raised shares of Arcturus Therapeutics from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, October 21st. Leerink Partners raised their price objective on shares of Arcturus Therapeutics from $13.00 to $19.00 and gave the stock an "outperform" rating in a report on Friday, October 9th. Finally, BTIG Research dropped their price objective on shares of Arcturus Therapeutics from $23.00 to $20.00 and set a "buy" rating for the company in a report on Thursday, September 24th.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock opened at $11.03 on Friday. The business has a 50 day simple moving average of $13.61 and a 200 day simple moving average of $8.99. The company has a market capitalization of $313.47 million, a PE ratio of -3.33 and a beta of 2.48. Arcturus Therapeutics has a one year low of $5.50 and a one year high of $17.96.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The biotechnology company reported ($0.84) earnings per share for the quarter, beating analysts' consensus estimates of ($1.00) by $0.16. The firm had revenue of $2.96 million for the quarter, compared to analysts' expectations of $3.11 million. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%. Equities analysts anticipate that Arcturus Therapeutics will post -3.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of large investors have recently bought and sold shares of the business. Versant Capital Management Inc grew its holdings in shares of Arcturus Therapeutics by 648.6% during the third quarter. Versant Capital Management Inc now owns 3,032 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 2,627 shares during the last quarter. Two Sigma Securities LLC acquired a new stake in shares of Arcturus Therapeutics in the second quarter valued at $80,000. Diversify Advisory Services LLC acquired a new stake in shares of Arcturus Therapeutics in the second quarter valued at $91,000. ADAR1 Capital Management LLC bought a new position in shares of Arcturus Therapeutics in the first quarter valued at about $116,000. Finally, Corient Private Wealth LP bought a new position in shares of Arcturus Therapeutics in the second quarter valued at about $117,000. 94.54% of the stock is currently owned by institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a biotechnology company headquartered in San Diego, California, focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company's platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acids into cells, as well as technologies for producing and administering mRNA and self-amplifying RNA.

The company's development programs address infectious diseases and rare genetic disorders. Arcturus has developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine known as ARCT-154, in collaboration with CSL.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.